 | • レポートコード：TPM-B04466 • 出版社/出版日：Transparency Market Research / 2018年1月 • レポート形態：英文、PDF、207ページ • 納品方法：Eメール • 産業分類：製薬・医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、炎症性腸疾患（IBD）治療の世界市場について調べ、炎症性腸疾患（IBD）治療の世界規模、市場動向、市場環境、薬物分類別分析、適応症別分析、 流通経路別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・炎症性腸疾患（IBD）治療の世界市場動向 ・炎症性腸疾患（IBD）治療の世界市場環境 ・炎症性腸疾患（IBD）治療の世界市場規模 ・炎症性腸疾患（IBD）治療の世界市場規模：薬物分類別 ・炎症性腸疾患（IBD）治療の世界市場規模：適応症別 ・炎症性腸疾患（IBD）治療の世界市場規模： 流通経路別 ・炎症性腸疾患（IBD）治療の世界市場：地域別市場規模・分析 ・炎症性腸疾患（IBD）治療の北米市場規模・予測 ・炎症性腸疾患（IBD）治療のアメリカ市場規模・予測 ・炎症性腸疾患（IBD）治療の中南米市場規模・予測 ・炎症性腸疾患（IBD）治療のヨーロッパ市場規模・予測 ・炎症性腸疾患（IBD）治療のアジア市場規模・予測 ・炎症性腸疾患（IBD）治療の日本市場規模・予測 ・炎症性腸疾患（IBD）治療の中国市場規模・予測 ・炎症性腸疾患（IBD）治療のインド市場規模・予測 ・炎症性腸疾患（IBD）治療の中東市場規模・予測 ・炎症性腸疾患（IBD）治療のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Global Inflammatory Bowel Disease (IBD) Treatment Market: Overview
Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract. The inflammatory bowel disease mainly comprises of Ulcerative colitis and Crohn’s disease. The ulcerative colitis primarily affects the large intestine and anus and it causes the inflammation sores in the inner lining of colon and rectum. The Crohn’s disease affects any part of gastrointestinal tract and unlike ulcerative colitis, it affects all the layers of gastrointestinal walls. The ulcerative colitis is more prevalent than that of Crohn’s disease. The IBD affects equally in men and women and has prevalence and incidence rates in developed countries than that of developing and under developed countries. The exact cause of inflammatory bowel disease are not well understood however, the combination of several factors such as autoimmune disorders, genetic factors, lifestyle related risks factors such as smoking, sedentary lifestyle, lack of exercise are likely to contribute to the development of symptoms of inflammatory bowel disease. The common symptoms of inflammatory bowel disease includes the severe abdominal cramps and pain, persistent diarrhea, occasional rectal bleeding. The IBD has no permanent cure and requires the lifelong disease management and treatment. Several medications such as corticosteroids, aminosalicyclates, immunomodulators, and biologic drugs such as TNF inhibitors and up to certain extent antibiotic drugs are prescribed to relive the symptoms of these diseases.
Global Inflammatory Bowel Disease (IBD) Treatment Market: Trends and Opportunities
The global IBD treatment market is projected to be primarily driven by the new product development and approvals, rising use of biologic drugs and biosimilar drugs for the treatment of IBD. The high prevalence and increasing incidence of Crohn’s disease and Ulcerative colitis disease in developed countries has fueled the development of novel therapeutics drugs. Genetic factors are found to induce the one of the forms of IBD. The children of parents having IBD are more likely to develop the symptoms of IBD. Studies have shown that around 5 to 20 % of affected population have developed the symptoms of IBD through inherited genes from parents. The Risk of developing IBD is higher when both the parents are affected with IBD. Biopharmaceutical companies have made the significant investments in R&D activities and there are large number of pipeline products in different stages of clinical approvals which are likely to commercialize during the forecast period. Recent launch and approvals of new drugs in North America and Europe as well as in Japan is projected to fuel the demand for IBD treatment drugs in near future.
Global Inflammatory Bowel Disease (IBD) Treatment Market: Key Segments
The global IBD treatment market is broadly categorized into four segments based on drug class, disease indication, distribution channel and region. By drug class, the global market is segmented into TNF inhibitors, aminosalicyclates, immunomodulators, and corticosteroids. The TNF inhibitors accounted for leading share of global IBD treatment market in 2016 and is projected to gain its market share by the end of 2025. The large share and growth of TNF inhibitors is attributed to rising use of biologic drugs as second line of treatment and approvals in key markets. Aminosalicyclates drug class is the second leading share holder of global IBD treatment market and is projected to substantially lose its market share to corticosteroids and immunomodulators during the forecast period. In terms of distribution channel, the global IBD treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
By geography, the global IBD treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. These regions have been further segmented by countries, drug class, and disease indication and distribution channels. North America and Europe accounted for leading share of global IBD treatment market and are projected to gain the market share by the end of 2025.
Global Inflammatory Bowel Disease (IBD) Treatment Market: Competitive Outlook k
The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global inflammatory bowel disease treatment market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc.
Global Inflammatory Bowel Disease Treatment Market is segmented as given below:
Global Inflammatory Bowel Disease Treatment Market, by Drug Class
TNF Inhibitors
Aminosalicyclates
Immunomodulators
Corticosteroids
Global Inflammatory Bowel Disease Treatment Market, by Disease Indication
Ulcerative Colitis
Crohn’s Disease
Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Inflammatory Bowel Disease Treatment Market, by Geography
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East and Africa
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Inflammatory Bowel Disease (IBD) Treatment market
Chapter 4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
Chapter 5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Porter’s five forces analysis
5.5. Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, 2015–2025
5.6. Global Inflammatory Bowel Disease (IBD) Treatment Market Outlook
5.7. Global Prevalence of Ulcerative Colitis
5.8. Global Prevalence of Crohn’s Disease
5.9. Pipeline Analysis
Chapter 6. Inflammatory Bowel Disease (IBD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
6.3.1. TNF Inhibitors
6.3.2. Aminosalicyclates
6.3.3. Immunomodulators
6.3.4. Corticosteroids
6.4. Market Attractiveness Analysis, by Drug Class
6.5. Key Trends
Chapter 7. Global Inflammatory Bowel Disease (IBD) Treatment Market Analysis and Forecasts, by Disease Indication
7.1. Key Findings
7.2. Introduction
7.3. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
7.3.1. Ulcerative Colitis
7.3.2. Crohn’s Disease
7.4. Market Attractiveness Analysis, by Disease Indication
7.5. Key Trends
Chapter 8. Global Inflammatory Bowel Disease (IBD) Treatment Market Analysis and Forecasts, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel
8.5. Key Trends
Chapter 9. Global Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region
9.5. Key Trends, By Region
Chapter 10. North America Inflammatory Bowel Disease (IBD) Treatment market Analysis andForecast
10.1. Key Findings
10.2. Market size (US$ Mn) Forecast, by Country, 2017-2025
10.2.1. U.S.
10.2.2. Canada
10.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
10.3.1. TNF Inhibitors
10.3.2. Aminosalicyclates
10.3.3. Immunomodulators
10.3.4. Corticosteroids
10.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
10.4.1. Ulcerative Colitis
10.4.2. Crohn’s Disease
10.5. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Drug Class
10.6.3. By Disease Indication
10.6.4. By Distribution Channel
Chapter 11. Europe Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
11.1. Key Findings
11.2. Market size (US$ Mn) Forecast By Country/Sub-region, 2017-2025
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
11.3.1. TNF Inhibitors
11.3.2. Aminosalicyclates
11.3.3. Immunomodulators
11.3.4. Corticosteroids
11.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
11.4.1. Ulcerative Colitis
11.4.2. Crohn’s Disease
11.5. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis
11.6.1. By Country/Sub-region
11.6.2. By Drug Class
11.6.3. By Disease Indication
11.6.4. By Distribution Channel
Chapter 12. Asia Pacific Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
12.4.1. TNF Inhibitors
12.4.2. Aminosalicyclates
12.4.3. Immunomodulators
12.4.4. Corticosteroids
12.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
12.5.1. Ulcerative Colitis
12.5.2. Crohn’s Disease
12.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy
12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
12.7.1. By Country/Sub-region
12.7.2. By Drug Class
12.7.3. By Disease Indication
12.7.4. By Distribution Channel
Chapter 13. Latin America Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country, 2017-2025
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
13.4.1. TNF Inhibitors
13.4.2. Aminosalicyclates
13.4.3. Immunomodulators
13.4.4. Corticosteroids
13.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
13.5.1. Ulcerative Colitis
13.5.2. Crohn’s Disease
13.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
13.6.1. Hospital Pharmacy
13.6.2. Retail Pharmacy
13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis
13.7.1. By Country/Sub-region
13.7.2. By Drug Class
13.7.3. By Disease Indication
13.7.4. By Distribution Channel
Chapter 14. Middle East and Africa Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East and Africa
14.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
14.4.1. TNF Inhibitors
14.4.2. Aminosalicyclates
14.4.3. Immunomodulators
14.4.4. Corticosteroids
14.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
14.5.1. Ulcerative Colitis
14.5.2. Crohn’s Disease
14.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
14.6.1. Hospital Pharmacy
14.6.2. Retail Pharmacy
14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis
14.7.1. By Country/Sub-region
14.7.2. By Drug Class
14.7.3. By Disease Indication
14.7.4. By Distribution Channel
Chapter 15. Competition Landscape
15.1. Global Inflammatory Bowel Disease (IBD) Treatment Market Share, by Company, 2016
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. Shire plc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
15.3.2. Pfizer, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
15.3.3. Janssen Biotech, Inc. (Johnson & Johnson)
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.4. Valeant Pharmaceuticals International, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.5. Allergan plc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.6. Takeda Pharmaceutical Company Limited.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.7. AbbVie, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.8. Novartis AG
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.9. UCB Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.10. Biogen Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
Table 01: Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 03: Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 04: Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 05: North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 06: North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 07: North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 08: North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 09: Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 10: Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 11: Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 12: Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 14: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 16: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 18: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 19: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 20: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 22: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 23: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 24: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025